Barclays downgrades Arena Pharmaceuticals (Nasdaq: ARNA) from Equalweight to Underweight. PT lowered from $4 to $3.

Barclays analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE